Regarding FDA approval, the market was told a result of some sort was expected late November. No update or info at all, so the market assumes the worst. It's the sensible thing to do.
Investors have been left in the lurch big time, especially those who acquired shares in the recent capital raise, which now seems it was very strategically timed.
